跳至主要内容
临床试验/CTRI/2020/10/028325
CTRI/2020/10/028325尚未招募未知

Comparative study of Tocilizumab Vs Itolizumab in covid 19 Patient â??Randomized control trial

AIIMS Patna0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age 18 to 60 years
  • 2. Virological diagnosis of SARS-CoV2 infection
  • 3. Patients who are in moderate ARDS following
  • COVID-19 infection, as defined by PaO2/FiO2
  • ratio of <200, or more than 25%
  • deterioration from the immediate previous
  • value within 24hrs in patient having
  • po2/fio2 >200.
  • 4. Baseline serum ferritin level >=400ng/mL or
  • IL-6 levels greater than 4 times the upper
  • limit of normal (ULN) would be included.

排除标准

  • 1. Known case of severe allergic reactions to
  • monoclonal antibodies
  • 2. Active tuberculosis (TB) infection
  • 3. History of inadequately treated tuberculosis
  • or latent tuberculosis
  • 4. Have received oral anti-rejection or immune-
  • suppressive drugs within the past 6 months
  • 5. Pregnant or breastfeeding, or positive
  • pregnancy test in a pre-dose examination
  • 6. Patients with known history of Hepatitis
  • B, Hepatitis C or HIV
  • 7. Absolute Neutrophils count (ANC) <1000 / mm3
  • 8. Platelets <50,000 / mm3
  • 9. Absolute Lymphocyte count (ALC): <500/mm3
  • 10. Very severe ARDS Pao2/Fio2<=100 with PEEP>=5
  • 11. ARDS due to others secondary infection/
  • bacterial sepsis (High procalcitonin value)
  • 12. Those patient who will be recruited for
  • another study

研究者

发起方
AIIMS Patna

相似试验